Mark N Levine

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. Levine M, Julian J, Bedard P, Eisen A, Trudeau M, Higgins B, et al. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. J Clin Oncol. 2016;34:1065-71 pubmed publisher
    ..001). The RS substantially influenced both oncologists' recommendations and patients' preferences for chemotherapy. The major effect was avoidance of chemotherapy when AOL indicated high or intermediate risk. ..
  2. Serrano P, Gafni A, Gu C, Gulenchyn K, Julian J, Law C, et al. Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial. J Oncol Pract. 2016;12:e765-74 pubmed publisher
    ..PET-CT was associated with limited clinical benefit and a nonsignificant increased cost. Universal funding of PET-CT in the management of patients with resectable colorectal cancer liver metastases does not seem justified. ..
  3. Laurie S, Hao D, Leighl N, Goffin J, Khomani A, Gupta A, et al. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 2017;104:65-69 pubmed publisher
    ..One of 12 tumour specimens had low amplification of FGFR-1. Dovitinib has minimal activity in previously-treated MPM. The role of the FGFR pathway in MPM remains unclear. ..

Detail Information

Publications3

  1. Levine M, Julian J, Bedard P, Eisen A, Trudeau M, Higgins B, et al. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. J Clin Oncol. 2016;34:1065-71 pubmed publisher
    ..001). The RS substantially influenced both oncologists' recommendations and patients' preferences for chemotherapy. The major effect was avoidance of chemotherapy when AOL indicated high or intermediate risk. ..
  2. Serrano P, Gafni A, Gu C, Gulenchyn K, Julian J, Law C, et al. Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial. J Oncol Pract. 2016;12:e765-74 pubmed publisher
    ..PET-CT was associated with limited clinical benefit and a nonsignificant increased cost. Universal funding of PET-CT in the management of patients with resectable colorectal cancer liver metastases does not seem justified. ..
  3. Laurie S, Hao D, Leighl N, Goffin J, Khomani A, Gupta A, et al. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 2017;104:65-69 pubmed publisher
    ..One of 12 tumour specimens had low amplification of FGFR-1. Dovitinib has minimal activity in previously-treated MPM. The role of the FGFR pathway in MPM remains unclear. ..